SARS-CoV-2-Diagnostics

DIRECT-Dx

Development of a sensitive antigen-based rapid test for the diagnostic of COVID-19

The project DIRECT-Dx aims to develop a diagnostic test that detects the presence of the SARS-CoV-2 virus directly from patient samples, without the need to access the virus’ DNA material. In collaboration with the academic partner Potsdam University and industry partner Preclinics, this project wants to characterize anti-SARS-CoV-2 antibodies and peptides, which are capable of binding to the virus without sample manipulation. Once specificity and sensitivity are established through standard methods of interaction analyses, we aim to develop a rapid detection system. In this case, the Virus-peptide or Virus-antibody interaction generates a visual signal in real-time, for example through color change, so that the assay could be used for home testing.

More Information about DIRECT-Dx on the Project website.

Project partners

preclinics GmbH

Universität Potsdam, AG Molekulare Bioanalytik

This Project is funded by the Federal Ministry of Education and Research

Grant Number: 03COV24

Further Projects

SARS-CoV-2-Diagnostics

TRAVEL-Dx

Development of a sensitive DNA-based rapid test for the diagnostics of COVID-19
SARS-CoV-2-Diagnostics

BEAD-Dx

Multiparameter test for the differential diagnostics of COVID-19
SARS-CoV-2-Diagnostics

EPI-Dx

Epidemiological investigation on peptide signatures, immunity, genetic predisposition as well as changes in SARS-CoV-2.
SARS-CoV-2-Diagnostics

VALIDATE-Dx

Appropriate and high quality study material is essential for the development of diagnostic tests.
SARS-CoV-2-Diagnostics

PEPTIDE-Dx

Can the identification of immunotopes serve as a basis for e.g. diagnostic tests?